Dr. Reddy's Launches 40 mg Doxycycline Capsules in the U.S.

HYDERABAD, India--Dr. Reddy's Laboratories Ltd. has announced the introduction of Doxycycline Capsules, 40 mg, into the U.S. market. This product is a generic equivalent of ORACEA® (doxycycline, USP) Capsules, 40 mg, which has been approved by the U.S. Food and Drug Administration (USFDA).

The newly launched Doxycycline Capsules, 40 mg, by Dr. Reddy's will be available in bottles containing 30 capsules. Each of these capsules comprises 26 mg of immediate-release pellets and 14 mg of delayed-release pellets, collectively equating to 40 mg of anhydrous doxycycline, USP.

Dr. Reddy's Laboratories Ltd., headquartered in Hyderabad, India, was founded in 1984. The company is dedicated to providing affordable and innovative medicines. Their product portfolio includes Active Pharmaceutical Ingredients (APIs), generics, branded generics, biosimilars, and over-the-counter (OTC) products. The primary therapeutic domains that Dr. Reddy's focuses on are gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology.

Dr. Reddy's Laboratories serves several major markets globally, including the USA, India, Russia & CIS countries, China, Brazil, and Europe. Known for its innovative approaches in the pharmaceutical industry, the company continues to invest in future-oriented businesses. Dr. Reddy's also emphasizes sustainability and environmental, social, and governance (ESG) actions, having released its first Sustainability Report in 2004. The company's current ESG goals include high standards in environmental stewardship, patient access and affordability, diversity, and governance.

With a purpose encapsulated in the message "Good Health Can’t Wait," Dr. Reddy's Laboratories continues to focus on advancing healthcare through its diverse and inclusive range of pharmaceutical products and services.